EE04581B1 - a1 ß1-integriiniretseptori inhibiitorite ja TGF-ß1 inhibiitorite kasutamine neeruhaiguse ravis - Google Patents

a1 ß1-integriiniretseptori inhibiitorite ja TGF-ß1 inhibiitorite kasutamine neeruhaiguse ravis

Info

Publication number: EE04581B1
Authority: EE; Estonia
Prior art keywords: alpha; inhibitors; integrin receptor; beta; treatment
Prior art date: 1998-05-22

Application number

EEP200000685A

Other languages

English (en)

Inventor

Cosgrove Dominic

Original Assignee

Boys Town National Research Hospital

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-22

Filing date

1999-05-19

Publication date

2006-02-15

1999-05-19 Application filed by Boys Town National Research Hospital filed Critical Boys Town National Research Hospital

2002-04-15 Publication of EE200000685A publication Critical patent/EE200000685A/et

2006-02-15 Publication of EE04581B1 publication Critical patent/EE04581B1/et

Links

108010055795 Integrin alpha1beta1 Proteins 0.000 title abstract 3
208000017169 kidney disease Diseases 0.000 title abstract 3
239000003112 inhibitor Substances 0.000 title abstract 2
108091006082 receptor inhibitors Proteins 0.000 title abstract 2
102000008186 Collagen Human genes 0.000 abstract 2
108010035532 Collagen Proteins 0.000 abstract 2
229920001436 collagen Polymers 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
206010018364 Glomerulonephritis Diseases 0.000 abstract 1
210000000585 glomerular basement membrane Anatomy 0.000 abstract 1
201000006370 kidney failure Diseases 0.000 abstract 1
238000010172 mouse model Methods 0.000 abstract 1
201000002793 renal fibrosis Diseases 0.000 abstract 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K3/00—Materials not provided for elsewhere
- C09K3/18—Materials not provided for elsewhere for application to surfaces to minimize adherence of ice, mist or water thereto; Thawing or antifreeze materials for application to surfaces
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Zoology (AREA)
Combustion & Propulsion (AREA)
Materials Engineering (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

EEP200000685A 1998-05-22 1999-05-19 a1 ß1-integriiniretseptori inhibiitorite ja TGF-ß1 inhibiitorite kasutamine neeruhaiguse ravis EE04581B1 (et)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US8658798P	1998-05-22	1998-05-22
US8876698A	1998-06-02	1998-06-02
US15048598A	1998-09-09	1998-09-09
PCT/US1999/011073 WO1999061040A2 (en)	1998-05-22	1999-05-19	USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE

Publications (2)

Publication Number	Publication Date
EE200000685A EE200000685A (et)	2002-04-15
EE04581B1 true EE04581B1 (et)	2006-02-15

Family

ID=56289911

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200000685A EE04581B1 (et)	1998-05-22	1999-05-19	a1 ß1-integriiniretseptori inhibiitorite ja TGF-ß1 inhibiitorite kasutamine neeruhaiguse ravis

Country Status (21)

Country	Link
EP (1)	EP1079843B1 (et)
JP (1)	JP2002516287A (et)
CN (1)	CN1187084C (et)
AT (1)	ATE359804T1 (et)
BR (1)	BR9911067A (et)
CA (1)	CA2329757C (et)
CZ (1)	CZ296262B6 (et)
DE (1)	DE69935853T2 (et)
DK (1)	DK1079843T3 (et)
EA (1)	EA004145B1 (et)
EE (1)	EE04581B1 (et)
ES (1)	ES2285841T3 (et)
HU (1)	HUP0202048A3 (et)
NO (1)	NO20005883L (et)
NZ (1)	NZ508317A (et)
PL (1)	PL345946A1 (et)
PT (1)	PT1079843E (et)
SG (1)	SG117434A1 (et)
SI (1)	SI1079843T1 (et)
TR (1)	TR200003432T2 (et)
WO (1)	WO1999061040A2 (et)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HK1043320A1 (zh)	1999-06-01	2002-09-13	Biogen, Inc.	Vla-1的一种阻塞性单系抗体，以及其治疗炎性失调的功用
US20070032853A1 (en)	2002-03-27	2007-02-08	Hossainy Syed F	40-O-(2-hydroxy)ethyl-rapamycin coated stent
EP1214091B1 (en) *	1999-09-14	2006-05-10	Biogen Idec MA Inc.	Therapies for chronic renal failure using one or more integrin antagonists
AU2001272100A1 (en) *	2000-03-09	2001-09-17	Genzyme Corporation	Use of tgf-beta antagonists to treat or to prevent loss of renal function
PL367324A1 (en)	2001-04-13	2005-02-21	Biogen, Inc.	Antibodies to vla-1
JP2006516024A (ja)	2002-11-01	2006-06-15	ボーイズタウンナショナルリサーチホスピタル	α１β１インテグリンの誘導性リガンドおよび使用
US20050118344A1 (en)	2003-12-01	2005-06-02	Pacetti Stephen D.	Temperature controlled crimping
EP2034830B1 (en)	2006-05-25	2014-09-03	Biogen Idec MA Inc.	Anti-vla-1 antibody for treating stroke
GB0911888D0 (en) *	2009-07-08	2009-08-19	Oxford Biodynamics Ltd	Method of treating age related disorders
ES2621863T3 (es)	2011-04-25	2017-07-05	Regulus Therapeutics Inc.	Compuestos de microARN y métodos para modular la actividad de miR-21
MX370199B (es)	2012-02-16	2019-12-05	Santarus Inc	Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
AR090825A1 (es)	2012-04-25	2014-12-10	Regulus Therapeutics Inc	COMPUESTO DE microARN Y METODOS DE MODULACION DE LA ACTIVIDAD DE miR-21
UA116639C2 (uk) *	2012-10-09	2018-04-25	Рег'Юлес Терап'Ютікс Інк.	Способи лікування синдрому альпорта
CN104450726A (zh) *	2013-09-17	2015-03-25	深圳华大基因科技有限公司	Col4a5基因突变体及其应用
CN104212806B (zh) *	2014-07-21	2017-05-17	深圳华大基因股份有限公司	Alport综合征新的突变致病基因及其编码蛋白和应用
US20230374141A1 (en) *	2020-10-05	2023-11-23	Father Flanagan's Boys' Home Doing Business As Boys Town National Research Hospital	Combination therapy for alport renal disease
CN112575074B (zh) *	2020-10-09	2022-12-27	中山大学	Nestin基因及蛋白在治疗器官纤维化中的应用
WO2023085396A1 (ja) *	2021-11-12	2023-05-19	Ｕｂｅ株式会社	アルポート症候群を治療または予防するための医薬組成物
CN114698592B (zh) *	2022-04-29	2022-11-04	中国医学科学院北京协和医院	一种干燥综合征肾损害小鼠模型的构建方法及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9519667D0 (en) *	1995-09-27	1995-11-29	Univ Manchester	Pharmaceutical composition

1999
- 1999-05-19 DE DE69935853T patent/DE69935853T2/de not_active Expired - Lifetime
- 1999-05-19 ES ES99923224T patent/ES2285841T3/es not_active Expired - Lifetime
- 1999-05-19 CN CNB998090247A patent/CN1187084C/zh not_active Expired - Fee Related
- 1999-05-19 EP EP99923224A patent/EP1079843B1/en not_active Expired - Lifetime
- 1999-05-19 CA CA2329757A patent/CA2329757C/en not_active Expired - Fee Related
- 1999-05-19 EA EA200001092A patent/EA004145B1/ru not_active IP Right Cessation
- 1999-05-19 NZ NZ508317A patent/NZ508317A/en unknown
- 1999-05-19 TR TR2000/03432T patent/TR200003432T2/xx unknown
- 1999-05-19 BR BR9911067-9A patent/BR9911067A/pt not_active IP Right Cessation
- 1999-05-19 AT AT99923224T patent/ATE359804T1/de not_active IP Right Cessation
- 1999-05-19 CZ CZ20004358A patent/CZ296262B6/cs not_active IP Right Cessation
- 1999-05-19 JP JP2000550500A patent/JP2002516287A/ja active Pending
- 1999-05-19 PL PL99345946A patent/PL345946A1/xx unknown
- 1999-05-19 SI SI9930967T patent/SI1079843T1/sl unknown
- 1999-05-19 EE EEP200000685A patent/EE04581B1/et not_active IP Right Cessation
- 1999-05-19 DK DK99923224T patent/DK1079843T3/da active
- 1999-05-19 SG SG200300701A patent/SG117434A1/en unknown
- 1999-05-19 WO PCT/US1999/011073 patent/WO1999061040A2/en not_active Ceased
- 1999-05-19 PT PT99923224T patent/PT1079843E/pt unknown
- 1999-05-19 HU HU0202048A patent/HUP0202048A3/hu unknown
2000
- 2000-11-21 NO NO20005883A patent/NO20005883L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NO20005883D0 (no)	2000-11-21
CA2329757A1 (en)	1999-12-02
EP1079843B1 (en)	2007-04-18
ES2285841T3 (es)	2007-11-16
BR9911067A (pt)	2001-02-06
PL345946A1 (en)	2002-01-14
PT1079843E (pt)	2007-06-26
DE69935853T2 (de)	2008-01-10
JP2002516287A (ja)	2002-06-04
WO1999061040A9 (en)	2001-02-01
EE200000685A (et)	2002-04-15
NO20005883L (no)	2001-01-17
HUP0202048A3 (en)	2006-11-28
SG117434A1 (en)	2005-12-29
ATE359804T1 (de)	2007-05-15
EA200001092A1 (ru)	2001-06-25
CN1310625A (zh)	2001-08-29
DE69935853D1 (de)	2007-05-31
DK1079843T3 (da)	2007-07-30
CZ20004358A3 (cs)	2002-01-16
SI1079843T1 (sl)	2007-10-31
NZ508317A (en)	2004-01-30
CN1187084C (zh)	2005-02-02
EA004145B1 (ru)	2004-02-26
TR200003432T2 (tr)	2001-03-21
WO1999061040A3 (en)	2000-01-27
CZ296262B6 (cs)	2006-02-15
WO1999061040A2 (en)	1999-12-02
EP1079843A2 (en)	2001-03-07
CA2329757C (en)	2013-11-19
HUP0202048A2 (en)	2002-10-28

Publication	Publication Date	Title
EE04581B1 (et)	2006-02-15	a1 ß1-integriiniretseptori inhibiitorite ja TGF-ß1 inhibiitorite kasutamine neeruhaiguse ravis
IL143901A0 (en)	2002-04-21	Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
BR0014078A (pt)	2002-12-31	Inibidores de fator xa
ES2235353T3 (es)	2005-07-01	Naftridonas para inhibir la proteina tirasina quinasa y proliferacion celular mediada por la quinasa del ciclo celular.
TR200103233T2 (tr)	2002-04-22	Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
AU5338301A (en)	2001-10-30	Methods and compositions for modulating alpha adrenergic receptor activity
BR0013219A (pt)	2002-04-23	Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto
BG105112A (bg)	2001-10-31	Средство с антидепресивно действие
AR049829A1 (es)	2006-09-06	Procedimiento y composiciones utiles para prevenir y/o tratar las pieles sensibles y/o secas
HUP0104688A2 (hu)	2002-03-28	Összetételek és eljárások a rákbetegség és a rákbetegséggel kapcsolódó csontveszteség megelőzéséhez és kezeléséhez
NO992282L (no)	1999-05-11	Benzonaftyridiner som bronkialterapentika
ATE234812T1 (de)	2003-04-15	Integrin antagonisten
BR0309095A (pt)	2005-02-09	Uso de osteoprotegerina para o tratamento e/ou prevenção de doença fibrótica
AU5338401A (en)	2001-10-30	Methods and compositions for modulating alpha adrenergic receptor activity
ES2216630T3 (es)	2004-10-16	Metodos de tratar la hipertension dependiente de la sal.
BRPI0415896A (pt)	2007-01-09	combinações compreendendo um inibidor de hsp90 e um inibidor de fosfodiesterase para tratamento ou prevenção de neoplasia
DK0946157T3 (da)	2002-07-08	Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte
MY136261A (en)	2008-09-30	Aldose reductase inhibition in preventing or reversing diabetic cardiomyopathy
BRPI0414724A (pt)	2006-11-21	combinação, composição farmacêutica, métodos para prevenir ou tratar aterosclerose em um animal de sangue quente e para prevenir eventos cardiovasculares em um animal de sangue quente, e, kit
TR200200278T2 (tr)	2002-06-21	Kalsilitik bileşimler
YU39598A (sh)	1999-09-27	Upotreba duloksetina i njegova farmaceutska smeša
DK1152757T3 (da)	2005-10-31	MMP-inhibitorer i bindevævsblödhed
DE50111407D1 (de)	2006-12-21	Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
DK0841937T4 (da)	2009-05-11	Anvendelse af betaglycan til reduktion af ardannelse
DE60009315D1 (de)	2004-05-13	Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung

Legal Events

Date	Code	Title	Description
2005-10-17	HC1A	Change of owner name
2007-02-15	KB4A	Valid patent at the end of a year	Effective date: 20061231
2008-02-15	KB4A	Valid patent at the end of a year	Effective date: 20071231
2009-02-16	KB4A	Valid patent at the end of a year	Effective date: 20081231
2010-02-15	MM4A	Lapsed by not paying the annual fees	Effective date: 20090519